While raised levels of monocyte chemoattractant protein 1 (MCP-1) have been observed in patients with chronic muscle pain, direct evidence for its role as an algogen in skeletal muscle is still lacking. In the rat, MCP-1 induces a dose-dependent mechanical hyperalgesia lasting for up to 6 weeks. Following recovery, rats exhibited a markedly prolonged hyperalgesia to an intramuscular injection of prostaglandin E2, hyperalgesic priming. Intrathecal pretreatment with isolectin B4 (IB4)-saporin, which selectively destroys IB4-positive (IB4+) nociceptors, markedly decreased MCP-1-induced hyperalgesia and prevented the subsequent development of priming. To evaluate the involvement of MCP-1 in stress-induced chronic pain we administered, intrathecally, antisense (AS) or mismatch oligodeoxynucleotides directed against CCR2 (the canonical receptor for MCP-1) mRNA, during the exposure to water-avoidance stress, a model of stress-induced persistent muscle pain. The AS treatment attenuated this hyperalgesia, whereas IB4-saporin abolished water-avoidance stress-induced muscle hyperalgesia and prevented stressinduced hyperalgesic priming. These results indicate that MCP-1 induces persistent muscle hyperalgesia and a state of latent chronic sensitization to other algogens, by action on its cognate receptor on IB4+ nociceptors. Because MCP-1 also contributes to stress-induced widespread chronic muscle pain, it should be considered as a player in chronic musculoskeletal pain syndromes.
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Introduction
Chronic muscle pain syndromes are very common and disabling, producing a large burden of economic losses related to health care expenses, decreased work productivity, and disability compensation [24] . It is often observed in the absence of a previous injury, and may exhibit features of a widespread pain syndrome. Remarkably, stress is well established to trigger and aggravate chronic muscle pain [24] . In spite of these distinctive clinical features, the mechanisms underlying chronic muscle pain still remain obscure, precluding the development of rational analgesic strategies.
The search for potential biomarkers and proalgesic agents of chronic muscle pain has identified a correlation between reported pain levels and raised plasma/local levels of some proinflammatory mediators. For example, a small (13 kDa) chemokine, the monocyte chemoattractant protein 1 (MCP-1, also known as chemokine [C-C motif] ligand 2 or CCL2), has been identified as a candidate algogen involved in fibromyalgia [7, 19, 67] and polymyalgia rheumatica [41] , which are characterized by intense widespread chronic muscle pain. In addition, some viral diseases, such as chikungunya fever, dengue fever, influenza A, and vesicular stomatitis, exhibit a widespread muscle pain concomitant to a marked rise in circulating levels of 21, 44, 55] . Because MCP-1 plays an important role as a chemotactic agent for monocyte/macrophages at the site of injury acting on its cognate receptor, CCR2 [63] , an indirect contribution of MCP-1 to pain by means of inflammatory cells is plausible. More recently, however, a direct proalgesic role for MCP-1 has been identified: indeed, intradermal injection of MCP-1 produces primary mechanical hyperalgesia with a rapid onset [16] , whereas the application of MCP-1 increases the excitability of C fibers [54] 
